AUGUSTUS
2019
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
In 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.
Result
Primary endpoint: Major or clinically relevant non-major bleeding
Apixaban vs warfarin HR 0.69; aspirin vs placebo HR 1.89 for bleeding.
- Subtopic
- AF + PCI
- Design
- 2×2 factorial RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Lopes RD, et al. N Engl J Med. 2019;380(16):1509-1524.doi 10.1056/NEJMoa1817083
Discussion & critique
Established apixaban plus a P2Y12 inhibitor without aspirin as the default. Triple therapy is now limited to roughly the first week after PCI.